This study investigates advanced solid tumor malignancies. The purpose of this study is to evaluate how the investigational medication works in people with this condition.
The study focuses on understanding the safety and effectiveness of the investigational medication. It evaluates how well participants tolerate the treatment and its potential effects.
- Who can participate: Adults aged 18 years and older with advanced or metastatic malignancies can participate. Key eligibility includes having a tumor that is evaluable or measurable and either having RAS mutations or glioblastoma.
- Study details: Participants will take the investigational medication orally twice a day. In Phase 1b, some participants will also take an autophagy inhibitor called hydroxychloroquine. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand